Effect of MPP2 and its DNA methylation levels on prognosis of colorectal cancer patients
Zhizhao Yang, Jiaxing Chen, Zhihao Fu, Dongfeng Deng, Yongqiang Cui, Zhilei Zhao, Xiao Zhang · 2024
Read Effect of MPP2 and its DNA methylation levels on prognosis of colorectal cancer patients by Zhizhao Yang, Jiaxing Chen, Zhihao Fu, Dongfeng Deng, Yongqiang Cui, Zhilei Zhao, Xiao Zhang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11533354.txt.
Description
Zhizhao Yang and colleagues study if the protein MPP2, and the methylation that silences it, can predict how colorectal cancer patients fare. Colorectal cancer has a poor outlook in part for lack of good biomarkers. The team got transcriptome and DNA methylation data for 380 patients from The Cancer Genome Atlas. They studied how MPP2 levels relate to methylation, outlook, immune checkpoints, and clinic traits.
They found MPP2 levels are guided down by its DNA methylation, leading to low levels in tumors. High levels were still a risk factor for outlook on their own, making the gene a candidate biomarker. Its levels tied closely to immune checkpoints and to immune cells in tumors, with CD4-positive T cells standing out. A pooled study of over 1,500 patients in four data sets confirmed MPP2 as a risk factor. In the lab, knocking MPP2 down cut cancer cell growth and movement a lot.
Catalog record
| CREATOR | Zhizhao Yang, Jiaxing Chen, Zhihao Fu, Dongfeng Deng, Yongqiang Cui, Zhilei Zhao, Xiao Zhang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |